blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3031908

EP3031908 - METHOD FOR PRODUCING DOPAMINERGIC NEURONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.10.2019
Database last updated on 08.10.2024
FormerThe patent has been granted
Status updated on  02.11.2018
FormerGrant of patent is intended
Status updated on  25.06.2018
FormerExamination is in progress
Status updated on  13.10.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome Chuo-ku
Osaka- shi, Osaka 541-0045 / JP
[2016/24]
Inventor(s)01 / SHOJI, Masanobu
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
 [2016/24]
Representative(s)Huenges, Martin
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2018/49]Huenges, Martin
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2016/24]Huenges, Martin
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date14834874.106.08.2014
[2016/24]
WO2014JP71352
Priority number, dateJP2013016306206.08.2013         Original published format: JP 2013163062
[2016/24]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015020234
Date:12.02.2015
Language:JA
[2015/06]
Type: A1 Application with search report 
No.:EP3031908
Date:15.06.2016
Language:EN
[2016/24]
Type: B1 Patent specification 
No.:EP3031908
Date:05.12.2018
Language:EN
[2018/49]
Search report(s)International search report - published on:JP12.02.2015
(Supplementary) European search report - dispatched on:EP18.11.2016
ClassificationIPC:A61K35/12, A61K35/30, A61L27/00, A61P25/16, C12N5/0793
[2016/51]
CPC:
C12N5/0619 (EP,US); A61K35/30 (EP,US); A61P25/00 (EP);
A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/28 (EP); C12N2500/38 (EP,US); C12N2501/01 (EP,US);
C12N2501/16 (EP,US); C12N2501/727 (EP,US) (-)
Former IPC [2016/24]C12N5/0793, A61K35/12, A61L27/00, A61P25/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG VON DOPAMINERGEN NEURONEN[2016/24]
English:METHOD FOR PRODUCING DOPAMINERGIC NEURONS[2016/24]
French:MÉTHODE DE PRODUCTION DE NEURONES DOPAMINERGIQUES[2016/24]
Entry into regional phase05.02.2016Translation filed 
05.02.2016National basic fee paid 
05.02.2016Search fee paid 
05.02.2016Designation fee(s) paid 
05.02.2016Examination fee paid 
Examination procedure05.02.2016Examination requested  [2016/24]
13.06.2017Amendment by applicant (claims and/or description)
13.10.2017Despatch of a communication from the examining division (Time limit: M04)
22.02.2018Reply to a communication from the examining division
26.06.2018Communication of intention to grant the patent
25.10.2018Fee for grant paid
25.10.2018Fee for publishing/printing paid
25.10.2018Receipt of the translation of the claim(s)
Opposition(s)06.09.2019No opposition filed within time limit [2019/46]
Fees paidRenewal fee
30.08.2016Renewal fee patent year 03
31.08.2017Renewal fee patent year 04
24.08.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.08.2014
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MK05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
BE31.08.2019
[2022/31]
Former [2021/34]HU06.08.2014
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
BE31.08.2019
Former [2021/32]HU06.08.2014
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
BE31.08.2019
Former [2021/26]AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
BE31.08.2019
Former [2020/38]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
BE31.08.2019
Former [2020/36]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
IE06.08.2019
LU06.08.2019
Former [2020/25]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU06.08.2019
Former [2020/17]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/50]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/48]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/39]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/37]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/35]AL05.12.2018
AT05.12.2018
CZ05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/33]AL05.12.2018
AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/30]AL05.12.2018
AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/26]AL05.12.2018
AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/25]AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/24]AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/23]AT05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/22]FI05.12.2018
LT05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/21]FI05.12.2018
LT05.12.2018
NO05.03.2019
Former [2019/20]LT05.12.2018
NO05.03.2019
Documents cited:Search[I]WO2010108008  (UNIV GEORGIA RES FOUND [US], et al) [I] 1-11 * page 23 * * claims 10-13 *;
 [E]WO2014124527  (UNIV HEALTH NETWORK [CA], et al) [E] 9,10* examples 4, 7 *
International search[X]WO2004081172  (RELIANCE LIFE SCIENCES PVT LTD [IN], et al);
 [X]  - HWANG D.Y. ET AL., "Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems", J. CELL . BIOCHEM., vol. 109, no. 2, pages 292 - 301, XP055314361

DOI:   http://dx.doi.org/10.1002/jcb.22411
 [X]  - KRIKS S. ET AL., "Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease", NATURE, vol. 480, no. 7378, pages 547 - 551, XP055271235

DOI:   http://dx.doi.org/10.1038/nature10648
 [X]  - JAEGER I. ET AL., "Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells", DEVELOPMENT, (201110), vol. 138, no. 20, pages 4363 - 4374, XP055314360

DOI:   http://dx.doi.org/10.1242/dev.066746
 [X]  - DENHAM M. ET AL., "Glycogen synthase kinase 3beta and activin/nodal inhibition in human embryonic stem cells induces a pre-neuroepithelial state that is required for specification to a floor plate cell lineage", STEM CELLS, (201211), vol. 30, no. 11, pages 2400 - 2411, XP055314359

DOI:   http://dx.doi.org/10.1002/stem.1204
 [X]  - KUPERSHMIDT L. ET AL., "The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases", J. NEUROCHEM., (200711), vol. 103, no. 3, pages 962 - 971, XP055139439

DOI:   http://dx.doi.org/10.1111/j.1471-4159.2007.04785.x
 [X]  - SUZUKI K. ET AL., "Activin A induces neuronal differentiation and survival via ALK4 in a SMAD-independent manner in a subpopulation of human neuroblastomas", BIOCHEM. BIOPHYS. RES. COMMUN., (20100409), vol. 394, no. 3, pages 639 - 645, XP055314358

DOI:   http://dx.doi.org/10.1016/j.bbrc.2010.03.039
Examination   - HARTIKKA J ET AL, "Cyclic AMP, but not basic FGF, increases the in vitro survival of mesencephalic dopaminergic neurons and protects them from MPP(+)-induced degeneration", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, (19920601), vol. 32, no. 2, doi:10.1002/JNR.490320208, ISSN 0360-4012, pages 190 - 201, XP002092604

DOI:   http://dx.doi.org/10.1002/jnr.490320208
    - PERRONE-CAPANO CARLA ET AL, "Genetic and epigenetic control of midbrain dopaminergic neuron development", INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, (2000), vol. 44, no. 6 Special Issue, ISSN 0214-6282, pages 679 - 687
    - SUN H D ET AL, "Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys", AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOL, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, (20070301), vol. 292, no. 3, doi:10.1152/AJPENDO.00089.2006, ISSN 0193-1849, pages E964 - E976, XP008085179

DOI:   http://dx.doi.org/10.1152/ajpendo.00089.2006
    - GOMEZ MARTA ET AL, "Sertoli-secreted FGF-2 induces PFKFB4 isozyme expression in mouse spermatogenic cells by activation of the MEK/ERK/CREB pathway", AMERICAN JOURNAL OF PHYSIOLOGY - ENDOCRINOLOGY AND METABOLISM, (201209), vol. 303, no. 6, ISSN 0193-1849(print), pages E695 - E707
    - C. C. Jiang ET AL, "Inhibition of MEK Sensitizes Human Melanoma Cells to Endoplasmic Reticulum Stress-Induced Apoptosis", Cancer research, (20071015), vol. 67, no. 20, doi:10.1158/0008-5472.CAN-07-2047, ISSN 0008-5472, pages 9750 - 9761, XP055166038

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-2047
by applicantUS2012094381
 WO2013067362
 JP2013163062
    - FASANO ET AL., CELL STEM CELL, (2010), vol. 6, pages 336 - 347
    - KRIKS ET AL., NATURE, (2011), vol. 480, pages 547 - 553
    - KIRKEBY ET AL., CELL REPORTS, (2012), vol. 1, pages 703 - 714
    - XI ET AL., STEM CELLS, (2012), vol. 30, pages 1655 - 1663
    - DENHAM ET AL., STEM CELLS, (2012), vol. 30, pages 2400 - 2411
    - EG CELL: PROC NATL ACAD SCI U S A., (1998), vol. 95, pages 13726 - 31
    - GS CELL: NATURE, (2008), vol. 456, pages 344 - 9
    - EVANS ET AL., NATURE, (1981), vol. 292, pages 154 - 6
    - MARTIN GR ET AL., PROC NATL ACAD SCI, (1981), vol. 78, pages 7634 - 8
    - THOMSON ET AL., SCIENCE, (1998), vol. 282, pages 1145 - 7
    - NAT BIOTECHNOL, (2008), vol. 26, pages 101 - 106
    - NATURE, (20080731), vol. 454, no. 7204, pages 646 - 50
    - CELL STEM CELL, (20090109), vol. 4, no. 1, pages 16 - 9
    - CELL STEM CELL., (20091106), vol. 5, no. 5, pages 491 - 503
    - CELL STEM CELL., (20090508), vol. 4, no. 5, pages 381 - 4
    - BREWER G.J. ET AL., J. NEUROSCI. RES., (1993), vol. 35, page 567
    - LING, N. ET AL., NATURE, (1986), vol. 321, pages 779 - 782
    - VALE, W. ET AL., NATURE, (1986), vol. 321, pages 776 - 779
    - NATURE NEUROSCIENCE, (1999), vol. 2, page 1137
    - N ENGL J MED., (2001), vol. 344, pages 710 - 9
    - NATURE BIOTECHNOLOGY, (2008), vol. 26, pages 101 - 106
    - CELL., (2007), vol. 131, pages 861 - 872
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.